An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
The world is entering a new era of the COVID-19 pandemic in which there is an increasing call for reliable antibody testing. To support decision making on the deployment of serology for either population screening or diagnostics, we present a detailed comparison of serological COVID-19 assays. We show that among the selected assays there is a wide diversity in assay performance in different scenarios and when correlated to virus neutralizing antibodies. The Wantai ELISA detecting total immunoglobulins against the receptor binding domain of SARS CoV-2, has the best overall characteristics to detect functional antibodies in different stages and severity of disease, including the potential to set a cut-off indicating the presence of protective antibodies. The large variety of available serological assays requires proper assay validation before deciding on deployment of assays for specific applications.
|Persistent URL||dx.doi.org/10.1038/s41467-020-17317-y, hdl.handle.net/1765/128638|
Geurts van Kessel, C.H, Okba, N.M.A, Igloi, Z. (Zsofia), Bogers, S. (Susanne), Embregts, C.W.E. (Carmen W. E.), Laksono, B.M, … Koopmans, M.P.G, D.V.M. (2020). An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nature Communications, 11(1). doi:10.1038/s41467-020-17317-y